Science & Innovation

Pipeline

Company Publications

Peer Reviewed Publications

Product

Announcements and Circulars

Listing Documents

Investor Presentation

Portfolio Advisory Board

Diabetes Advisory Board

Investor Relations

Corporate Governance

Financial Report

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Financial Report

Company Overview

Pipeline

Team

News

Mar 19, 2021

Hua Medicine Announces 2020 Annual Results

Hua Medicine (the"Company", Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). During the Reporting Period, the Company continued to advance various clinical trials and R&D investments, successfully completed two Phase III registration trials for dorzagliatin in China, and achieved remarkable results in preparing for dorzagliatin's commercialization.

Dec 18, 2020

Hua Medicine Successfully Completes Its Registration Phase III Trials. Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

Hua Medicine (the"Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced

Dec 17, 2020

Hua Medicine Announces the Commercialization Cooperation with Raybow Pharmaceutical

Hua Medicine (the "Company", Stock Code: 2552.HK) today announces that it has entered into a commercial supply agreement with Zhejiang Raybow Pharmaceutical Co., Ltd. ("Raybow Pharmaceutical"). As a future major supplier of dorzagliatin, the global first-in-class oral drug for the treatment of Type 2 diabetes, Raybow Pharmaceutical will supply Hua Medicine with active pharmaceutical ingredients ("API") after the commercial launch of dorzagliatin in China.